The nation of Zimbabwe has turned down a significant US health deal valued at 367 million US dollars (£272m) over five years because of the United States' request for sensitive data.
This rejection was revealed after a internal memorandum from December was leaked, which showed Head of State Emmerson Mnangagwa felt the deal was "lopsided".
A government representative has since clarified that the US was requesting biological samples for scientific study and commercial purposes while refused to guarantee the resulting advantages from future medical innovations.
"We are forced to start the difficult and regrettable task of winding down our health aid in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy said the US had furnished over $1.9bn in health funding to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has appealed for further talks to reach a deal suitable to all parties so the country's critical HIV treatment initiative can be sustained.
Broader Context
This development follows a comparable case in neighbouring Kenya, where a high court suspended a related health funding agreement following concerns were raised about the safety of Kenyans' medical information.
Since resuming the presidency last year, US President Donald Trump has slashed overseas assistance and closed the key foreign aid agency.
The agency had managed assistance for the American government, but Trump argued its spending was "wasteful" and his government was pursuing government-to-government deals to enhance openness and responsibility.
According to statements, 16 nations in Africa have to date signed similar agreements, representing more than $18.3bn in new funding.
Specifics of the Rejected Deal
The funds for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this collaboration would have delivered extraordinary benefits for the people of Zimbabwe, especially the 1.2 million currently receiving antiretroviral therapy via US-supported initiatives," the Ambassador said.
However, official spokesman Nick Mangwana said the proposed deal was "unfair".
"The proposal required Zimbabwe to surrender its biological resources and data indefinitely, with no equivalent promise of access to any medical innovations – like vaccines, diagnostics, or treatments – that might be developed from that shared data," his statement read.
"Put simply, our country would provide the raw materials for medical research with no assurance that the resulting innovations would be available to our people if a new pandemic arise."
National Interest and International Frameworks
Mangwana further pointed out that the American exit from the global health body and its pursuit of one-on-one health agreements were upending systems previously set up via the international organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing scheme designed to manage potential global health emergencies.
"This mechanism is designed to ensure that when a country provides its samples, the benefits – including medicines and cures – are distributed fairly, not commercialised solely by those with the resources to create them."
These objections regarding the US deal "should not be misconstrued as anti-American sentiment," Mangwana stressed.
"We welcome ongoing dialogue with our American counterparts on how subsequent collaboration could be designed in a manner that honours the independence and dignity of both nations."
Health Experts Reaction
A leading public health body said it recognised the government's concerns, but suggested that negotiations need to persist given that much of the country's HIV programmes depended on external financing.
"Where technical issues exist, such as those involving data governance or agreement terms, these can often be addressed via technical clarification and negotiated safeguards," it added.
The halted deal emphasises the complex challenges between accepting vital foreign assistance and protecting local interests in an ever more data-driven world.